NCT06649331 2026-03-17
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Fudan University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05176080 2024-12-17
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Henan Cancer Hospital
Phase 1/2 Terminated
NCT06516289 2024-12-12
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Fudan University
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05999149 2024-02-21
BCTOP-T-N01
Fudan University
Phase 3 Recruiting
NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
NCT04733417 2023-04-13
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT04129996 2022-01-11
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
Phase 2 Unknown